Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.24
OTCPK:GLAXF's Cash to Debt is ranked lower than
85% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. OTCPK:GLAXF: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:GLAXF' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.46 Max: N/A
Current: 0.24
Equity to Asset 0.01
OTCPK:GLAXF's Equity to Asset is ranked lower than
97% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. OTCPK:GLAXF: 0.01 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:GLAXF' s Equity to Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.24 Max: 0.4
Current: 0.01
0.01
0.4
Interest Coverage 1.96
OTCPK:GLAXF's Interest Coverage is ranked lower than
91% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. OTCPK:GLAXF: 1.96 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:GLAXF' s Interest Coverage Range Over the Past 10 Years
Min: 0.81  Med: 9.42 Max: 22.2
Current: 1.96
0.81
22.2
F-Score: 5
Z-Score: 1.19
M-Score: -2.63
WACC vs ROIC
9.40%
3.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.33
OTCPK:GLAXF's Operating margin (%) is ranked lower than
58% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. OTCPK:GLAXF: 5.33 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:GLAXF' s Operating margin (%) Range Over the Past 10 Years
Min: 1.68  Med: 28.24 Max: 34.91
Current: 5.33
1.68
34.91
Net-margin (%) 0.12
OTCPK:GLAXF's Net-margin (%) is ranked lower than
73% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. OTCPK:GLAXF: 0.12 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:GLAXF' s Net-margin (%) Range Over the Past 10 Years
Min: 0.12  Med: 19.36 Max: 23.2
Current: 0.12
0.12
23.2
ROE (%) 0.75
OTCPK:GLAXF's ROE (%) is ranked lower than
68% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.85 vs. OTCPK:GLAXF: 0.75 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:GLAXF' s ROE (%) Range Over the Past 10 Years
Min: 0.75  Med: 61.93 Max: 84.89
Current: 0.75
0.75
84.89
ROA (%) 0.06
OTCPK:GLAXF's ROA (%) is ranked lower than
67% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. OTCPK:GLAXF: 0.06 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:GLAXF' s ROA (%) Range Over the Past 10 Years
Min: 0.06  Med: 13.04 Max: 20.43
Current: 0.06
0.06
20.43
ROC (Joel Greenblatt) (%) 14.14
OTCPK:GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.35 vs. OTCPK:GLAXF: 14.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:GLAXF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 14.14  Med: 85.34 Max: 107.42
Current: 14.14
14.14
107.42
Revenue Growth (3Y)(%) -4.20
OTCPK:GLAXF's Revenue Growth (3Y)(%) is ranked lower than
74% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. OTCPK:GLAXF: -4.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:GLAXF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.2  Med: 5.15 Max: 15.3
Current: -4.2
-4.2
15.3
EBITDA Growth (3Y)(%) -18.40
OTCPK:GLAXF's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. OTCPK:GLAXF: -18.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:GLAXF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.4  Med: 6.7 Max: 17.4
Current: -18.4
-18.4
17.4
EPS Growth (3Y)(%) -17.80
OTCPK:GLAXF's EPS Growth (3Y)(%) is ranked higher than
74% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.40 vs. OTCPK:GLAXF: -17.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:GLAXF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.3  Med: 4.85 Max: 51.3
Current: -17.8
-30.3
51.3
» OTCPK:GLAXF's 10-Y Financials

Financials (Next Earnings Date: 2016-10-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:ABBV, NYSE:SNY, NYSE:BMY, NYSE:LLY, NYSE:AZN, OTCPK:BAYRY, OTCPK:SZUKF, OTCPK:ALPMY, NYSE:MRK, OTCPK:OTSKF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, NYSE:NVS, OTCPK:KYKOF, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:MAYNF, NAS:GWPH, NAS:HCM » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GSK.USA,
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

GlaxoSmithKline PLC was incorporated on 6 December 1999 in the United Kingdom. The Company creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led healthcare company that researches and develops products in three areas - pharmaceutical, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatrics and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. It has products in four main categories: Oral care, Nutritional, Total wellness, and Skin health. Its brands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.

Ratios

vs
industry
vs
history
Forward P/E 15.87
GLAXF's Forward P/E is ranked higher than
56% of the 68 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.86 vs. GLAXF: 15.87 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 27.32
GLAXF's Price/Owner Earnings (ttm) is ranked higher than
62% of the 276 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.00 vs. GLAXF: 27.32 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GLAXF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.81  Med: 16.55 Max: 45.91
Current: 27.32
4.81
45.91
P/B 140.08
GLAXF's P/B is ranked lower than
100% of the 696 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. GLAXF: 140.08 )
Ranked among companies with meaningful P/B only.
GLAXF' s P/B Range Over the Past 10 Years
Min: 5.48  Med: 9.35 Max: 143.64
Current: 140.08
5.48
143.64
P/S 3.20
GLAXF's P/S is ranked lower than
53% of the 693 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. GLAXF: 3.20 )
Ranked among companies with meaningful P/S only.
GLAXF' s P/S Range Over the Past 10 Years
Min: 1.94  Med: 2.81 Max: 4.22
Current: 3.2
1.94
4.22
PFCF 53.67
GLAXF's PFCF is ranked lower than
76% of the 193 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.96 vs. GLAXF: 53.67 )
Ranked among companies with meaningful PFCF only.
GLAXF' s PFCF Range Over the Past 10 Years
Min: 8.24  Med: 17.01 Max: 135.68
Current: 53.67
8.24
135.68
POCF 21.66
GLAXF's POCF is ranked lower than
60% of the 255 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.22 vs. GLAXF: 21.66 )
Ranked among companies with meaningful POCF only.
GLAXF' s POCF Range Over the Past 10 Years
Min: 6.61  Med: 12.6 Max: 27.31
Current: 21.66
6.61
27.31
EV-to-EBIT 71.11
GLAXF's EV-to-EBIT is ranked lower than
89% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.25 vs. GLAXF: 71.11 )
Ranked among companies with meaningful EV-to-EBIT only.
GLAXF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.6 Max: 72.6
Current: 71.11
6.3
72.6
EV-to-EBITDA 34.49
GLAXF's EV-to-EBITDA is ranked lower than
77% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.16 vs. GLAXF: 34.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLAXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.1 Max: 35.2
Current: 34.49
5.6
35.2
Shiller P/E 17.14
GLAXF's Shiller P/E is ranked higher than
91% of the 158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.89 vs. GLAXF: 17.14 )
Ranked among companies with meaningful Shiller P/E only.
GLAXF' s Shiller P/E Range Over the Past 10 Years
Min: 11.71  Med: 15 Max: 20.38
Current: 17.14
11.71
20.38
Current Ratio 0.93
GLAXF's Current Ratio is ranked lower than
89% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. GLAXF: 0.93 )
Ranked among companies with meaningful Current Ratio only.
GLAXF' s Current Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.27 Max: 1.78
Current: 0.93
0.93
1.78
Quick Ratio 0.63
GLAXF's Quick Ratio is ranked lower than
91% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. GLAXF: 0.63 )
Ranked among companies with meaningful Quick Ratio only.
GLAXF' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 0.99 Max: 1.42
Current: 0.63
0.63
1.42
Days Inventory 202.72
GLAXF's Days Inventory is ranked lower than
83% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.58 vs. GLAXF: 202.72 )
Ranked among companies with meaningful Days Inventory only.
GLAXF' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 190.92 Max: 202.72
Current: 202.72
167.28
202.72
Days Sales Outstanding 86.98
GLAXF's Days Sales Outstanding is ranked lower than
58% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.99 vs. GLAXF: 86.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLAXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 74.32 Max: 93.9
Current: 86.98
54.62
93.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.20
GLAXF's Dividend Yield is ranked higher than
95% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.55 vs. GLAXF: 5.20 )
Ranked among companies with meaningful Dividend Yield only.
GLAXF' s Dividend Yield Range Over the Past 10 Years
Min: 2.72  Med: 5.08 Max: 6.24
Current: 5.2
2.72
6.24
Dividend Growth (3y) 1.90
GLAXF's Dividend Growth (3y) is ranked lower than
65% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. GLAXF: 1.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
GLAXF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -12.6  Med: 7 Max: 20.8
Current: 1.9
-12.6
20.8
Forward Dividend Yield 4.66
GLAXF's Forward Dividend Yield is ranked higher than
95% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.49 vs. GLAXF: 4.66 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 7.19
GLAXF's Yield on cost (5-Year) is ranked higher than
92% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. GLAXF: 7.19 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GLAXF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.76  Med: 7.03 Max: 8.63
Current: 7.19
3.76
8.63
3-Year Average Share Buyback Ratio -2.00
GLAXF's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 430 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. GLAXF: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLAXF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.3  Med: 1.2 Max: 4.7
Current: -2
-20.3
4.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.54
GLAXF's Price/Projected FCF is ranked higher than
50% of the 291 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. GLAXF: 2.54 )
Ranked among companies with meaningful Price/Projected FCF only.
GLAXF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.61 Max: 21.79
Current: 2.54
0.97
21.79
Price/Median PS Value 1.14
GLAXF's Price/Median PS Value is ranked higher than
52% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. GLAXF: 1.14 )
Ranked among companies with meaningful Price/Median PS Value only.
GLAXF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.16 Max: 3.33
Current: 1.14
0.71
3.33
Earnings Yield (Greenblatt) (%) 1.40
GLAXF's Earnings Yield (Greenblatt) (%) is ranked lower than
62% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. GLAXF: 1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLAXF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.4  Med: 9.4 Max: 15.8
Current: 1.4
1.4
15.8
Forward Rate of Return (Yacktman) (%) 0.04
GLAXF's Forward Rate of Return (Yacktman) (%) is ranked lower than
65% of the 330 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.68 vs. GLAXF: 0.04 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GLAXF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -0.1  Med: 12.5 Max: 34.3
Current: 0.04
-0.1
34.3

More Statistics

Revenue (TTM) (Mil) $36,959
EPS (TTM) $ 0.01
Beta1.19
Short Percentage of Float0.00%
52-Week Range $18.45 - 22.98
Shares Outstanding (Mil)4,872.40

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 34,738 36,148 37,146 43,376
EPS ($) 1.31 1.36 1.30 1.64
EPS w/o NRI ($) 1.31 1.36 1.30 1.64
EPS Growth Rate
(3Y to 5Y Estimate)
4.95%
Dividends Per Share ($) 1.16 1.09 1.06 1.06
» More Articles for OTCPK:GLAXF

Headlines

Articles On GuruFocus.com
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
GlaxoSmithKline's Dividend Health Aug 09 2016 
Tweedy Browne 2nd Quarter Shareholder Letter Aug 01 2016 
GlaxoSmithKline’s Sideways Dance May Pay Off in the Long Run Jul 22 2016 
Why Berkshire Hathaway Dumped Johnson & Johnson Jul 19 2016 
Andreas Halvorsen's Viking Global Gets Control of Stakes in 2 Companies for Backing Hot Biotech Jul 14 2016 
Investing in Big Pharma: Pointers on Pfizer Jul 14 2016 
Getting to Know VBI Vaccines Jul 13 2016 
Jeff Auxier Sells Precision Castparts, AT&T, Microsoft Jun 23 2016 

More From Other Websites
5 Stocks to Sell Now Before It's Too Late Sep 24 2016
[$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience Sep 23 2016
Hard to swallow: emerging markets get tougher for drugmakers Sep 22 2016
Hard to swallow: emerging markets get tougher for drugmakers Sep 22 2016
Hard to swallow - emerging markets get tougher for drugmakers Sep 22 2016
Hard to swallow: emerging markets get tougher for drugmakers Sep 22 2016
HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target Sep 22 2016
What GlaxoSmithKline plc’s choice of CEO means for shareholders Sep 22 2016
Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment Sep 21 2016
Is Sinclair Pharma plc a better bet than GlaxoSmithKline plc? Sep 21 2016
Inside the 10-Year, $1 Billion Battle for the Next Critical Antibiotic Sep 21 2016
PRESS DIGEST- Financial Times - Sept 21 Sep 20 2016
Equities in waiting mode ahead of bank decisions Sep 20 2016
Medecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix Sep 20 2016
Glaxo becomes seventh female-led FTSE 100 firm Sep 20 2016
GSK appoints Emma Walmsley as Sir Andrew Witty's successor Sep 20 2016
GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive Sep 20 2016
Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
Big Pharma’s Latest Breakthrough: Choosing Its First Female CEO Sep 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)